Last 12 months
Inside the activity.
0 purchase rows · 31 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 5 |
| Dec 2025 | 0 | 4 |
| Jan 2026 | 0 | 4 |
| Feb 2026 | 0 | 4 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 3 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 08, 2019 Filed Apr 10, 2019 19:22 UTC |
Farrell Michael J.Chief Executive Officer
|
SaleResMed Common Stock | 6,651 | $100.82 | $670,553.82 |
DisclosureSEC source: 0001127602-19-015159 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,282 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $100.45 to $101.07. The price reported above reflects the weighted average sale price. Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 19:22 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock | 6,651 | $43.63 | $290,183.13 |
DisclosureSEC source: 0001127602-19-015159 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,933 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| April 03, 2019 Filed Apr 5, 2019 20:52 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 4,457 | $0.00 Strike: $51.25 | $0.00 |
DisclosureSEC source: 0001127602-19-014941 · form4.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Commmon Stock · 4,457 shares Expires 2020-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| April 03, 2019 Filed Apr 5, 2019 20:52 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 4,457 | $105.21 | $468,920.97 |
DisclosureSEC source: 0001127602-19-014941 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,002 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| April 03, 2019 Filed Apr 5, 2019 20:52 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 4,457 | $51.25 | $228,421.25 |
DisclosureSEC source: 0001127602-19-014941 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,459 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| April 02, 2019 Filed Apr 3, 2019 20:29 UTC |
McHale RichardPresident, RC Business
|
Exercise / conversionResmed Stock Option Plan · Derivative | 21,616 | $0.00 Strike: $58.24 | $0.00 |
DisclosureSEC source: 0001127602-19-014605 · form4.xml · derivative · entry 12 McHale Richard · CIK 0001715326 · President, RC Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 21,616 shares Expires 2022-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| April 02, 2019 Filed Apr 3, 2019 20:29 UTC |
McHale RichardPresident, RC Business
|
Exercise / conversionResmed Stock Option Plan · Derivative | 4,907 | $0.00 Strike: $58.24 | $0.00 |
DisclosureSEC source: 0001127602-19-014605 · form4.xml · derivative · entry 11 McHale Richard · CIK 0001715326 · President, RC Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 4,907 shares Expires 2022-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| April 02, 2019 Filed Apr 3, 2019 20:29 UTC |
McHale RichardPresident, RC Business
|
SaleResMed Common Stock | 21,616 | $105.00 | $2,269,680.00 |
DisclosureSEC source: 0001127602-19-014605 · form4.xml · nonDerivative · entry 8 McHale Richard · CIK 0001715326 · President, RC Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,404 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| April 02, 2019 Filed Apr 3, 2019 20:29 UTC |
McHale RichardPresident, RC Business
|
Exercise / conversionResMed Common Stock | 21,616 | $58.24 | $1,258,915.84 |
DisclosureSEC source: 0001127602-19-014605 · form4.xml · nonDerivative · entry 7 McHale Richard · CIK 0001715326 · President, RC Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,020 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| April 02, 2019 Filed Apr 3, 2019 20:29 UTC |
McHale RichardPresident, RC Business
|
SaleResMed Common Stock | 4,907 | $105.00 | $515,235.00 |
DisclosureSEC source: 0001127602-19-014605 · form4.xml · nonDerivative · entry 6 McHale Richard · CIK 0001715326 · President, RC Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,404 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| April 02, 2019 Filed Apr 3, 2019 20:29 UTC |
McHale RichardPresident, RC Business
|
Exercise / conversionResMed Common Stock | 4,907 | $58.24 | $285,783.68 |
DisclosureSEC source: 0001127602-19-014605 · form4.xml · nonDerivative · entry 5 McHale Richard · CIK 0001715326 · President, RC Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,311 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 20:29 UTC |
McHale RichardPresident, RC Business
|
Exercise / conversionResmed Stock Option Plan · Derivative | 1,079 | $0.00 Strike: $58.24 | $0.00 |
DisclosureSEC source: 0001127602-19-014605 · form4.xml · derivative · entry 10 McHale Richard · CIK 0001715326 · President, RC Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,616 Underlying: ResMed Common Stock · 1,079 shares Expires 2022-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 20:29 UTC |
McHale RichardPresident, RC Business
|
Exercise / conversionResmed Stock Option Plan · Derivative | 244 | $0.00 Strike: $58.24 | $0.00 |
DisclosureSEC source: 0001127602-19-014605 · form4.xml · derivative · entry 9 McHale Richard · CIK 0001715326 · President, RC Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,907 Underlying: ResMed Common Stock · 244 shares Expires 2022-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 20:29 UTC |
McHale RichardPresident, RC Business
|
SaleResMed Common Stock | 1,079 | $105.05 | $113,348.95 |
DisclosureSEC source: 0001127602-19-014605 · form4.xml · nonDerivative · entry 4 McHale Richard · CIK 0001715326 · President, RC Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,404 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 20:29 UTC |
McHale RichardPresident, RC Business
|
Exercise / conversionResMed Common Stock | 1,079 | $58.24 | $62,840.96 |
DisclosureSEC source: 0001127602-19-014605 · form4.xml · nonDerivative · entry 3 McHale Richard · CIK 0001715326 · President, RC Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,483 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 20:29 UTC |
McHale RichardPresident, RC Business
|
SaleResMed Common Stock | 244 | $105.05 | $25,632.20 |
DisclosureSEC source: 0001127602-19-014605 · form4.xml · nonDerivative · entry 2 McHale Richard · CIK 0001715326 · President, RC Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,404 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 20:29 UTC |
McHale RichardPresident, RC Business
|
Exercise / conversionResMed Common Stock | 244 | $58.24 | $14,210.56 |
DisclosureSEC source: 0001127602-19-014605 · form4.xml · nonDerivative · entry 1 McHale Richard · CIK 0001715326 · President, RC Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,648 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 15:53 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 3,000 | $104.96 | $314,880.00 |
DisclosureSEC source: 0001127602-19-014410 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,390 F1 · kind: The transaction was conducted under a Rule 10b5-1 Plan. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 14:50 UTC |
Hollingshead JamesPresident, Sleep Business
|
Exercise / conversionResMed Common Stock Options · Derivative | 800 | $0.00 Strike: $58.24 | $0.00 |
DisclosureSEC source: 0001127602-19-014404 · form4.xml · derivative · entry 4 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,438 Underlying: ResMed Commmon Stock · 800 shares Expires 2022-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 Plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 14:50 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 800 | $104.96 | $83,968.00 |
DisclosureSEC source: 0001127602-19-014404 · form4.xml · nonDerivative · entry 3 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,657 F1 · kind: The transaction was conducted under a Rule 10b5-1 Plan. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 14:50 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 800 | $104.96 | $83,968.00 |
DisclosureSEC source: 0001127602-19-014404 · form4.xml · nonDerivative · entry 2 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,457 F1 · kind: The transaction was conducted under a Rule 10b5-1 Plan. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 14:50 UTC |
Hollingshead JamesPresident, Sleep Business
|
Exercise / conversionResMed Common Stock | 800 | $58.24 | $46,592.00 |
DisclosureSEC source: 0001127602-19-014404 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,257 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 Plan. Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 21:31 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
Exercise / conversionResMed Common Stock Options · Derivative | 3,307 | $0.00 Strike: $43.63 | $0.00 |
DisclosureSEC source: 0001127602-19-012302 · form4.xml · derivative · entry 4 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,144 Underlying: ResMed Commmon Stock · 3,307 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 21:31 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
SaleResMed Common Stock | 991 | $100.90 | $99,991.90 |
DisclosureSEC source: 0001127602-19-012302 · form4.xml · nonDerivative · entry 3 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Indirect · Douglas Family Trust Disclosed balance after: 153,335 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 21:31 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
SaleResMed Common Stock | 3,307 | $100.90 | $333,676.30 |
DisclosureSEC source: 0001127602-19-012302 · form4.xml · nonDerivative · entry 2 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,297 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 21:31 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
Exercise / conversionResMed Common Stock | 3,307 | $43.63 | $144,284.41 |
DisclosureSEC source: 0001127602-19-012302 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| March 11, 2019 Filed Mar 13, 2019 00:15 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 6,651 | $0.00 Strike: $43.63 | $0.00 |
DisclosureSEC source: 0001567619-19-006759 · doc1.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,157 Underlying: ResMed Commmon Stock · 6,651 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 annually. Read SEC document |
| March 11, 2019 Filed Mar 13, 2019 00:15 UTC |
Farrell Michael J.Chief Executive Officer
|
SaleResMed Common Stock | 6,651 | $101.05 | $672,083.55 |
DisclosureSEC source: 0001567619-19-006759 · doc1.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,282 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $100.89 to $101.20. The price reported above reflects the weighted average sale price. Read SEC document |
| March 11, 2019 Filed Mar 13, 2019 00:15 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock | 6,651 | $43.63 | $290,183.13 |
DisclosureSEC source: 0001567619-19-006759 · doc1.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,933 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| March 04, 2019 Filed Mar 5, 2019 18:59 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 4,457 | $0.00 Strike: $51.25 | $0.00 |
DisclosureSEC source: 0001567619-19-006100 · doc1.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,457 Underlying: ResMed Common Stock · 4,457 shares Expires 2020-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| March 04, 2019 Filed Mar 5, 2019 18:59 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 4,457 | $103.61 | $461,789.77 |
DisclosureSEC source: 0001567619-19-006100 · doc1.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,002 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| March 04, 2019 Filed Mar 5, 2019 18:59 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 4,457 | $51.25 | $228,421.25 |
DisclosureSEC source: 0001567619-19-006100 · doc1.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,459 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 15:07 UTC |
Hollingshead JamesPresident, Sleep Business
|
Exercise / conversionResMed Common Stock Options · Derivative | 800 | $0.00 Strike: $58.24 | $0.00 |
DisclosureSEC source: 0001567619-19-005879 · doc1.xml · derivative · entry 4 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,238 Underlying: ResMed Commmon Stock · 800 shares Expires 2022-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 15:07 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 800 | $102.80 | $82,240.00 |
DisclosureSEC source: 0001567619-19-005879 · doc1.xml · nonDerivative · entry 3 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,457 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 15:07 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 800 | $102.80 | $82,240.00 |
DisclosureSEC source: 0001567619-19-005879 · doc1.xml · nonDerivative · entry 2 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,257 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 15:07 UTC |
Hollingshead JamesPresident, Sleep Business
|
Exercise / conversionResMed Common Stock | 800 | $58.24 | $46,592.00 |
DisclosureSEC source: 0001567619-19-005879 · doc1.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,057 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 15:05 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 3,000 | $103.00 | $309,000.00 |
DisclosureSEC source: 0001567619-19-005878 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,390 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| February 27, 2019 Filed Feb 28, 2019 18:30 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
Exercise / conversionResMed Common Stock Options · Derivative | 6,876 | $0.00 Strike: $43.63 | $0.00 |
DisclosureSEC source: 0001567619-19-005560 · doc1.xml · derivative · entry 3 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Commmon Stock · 6,876 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| February 27, 2019 Filed Feb 28, 2019 18:30 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
Exercise / conversionResMed Common Stock | 6,876 | $43.63 | $299,999.88 |
DisclosureSEC source: 0001567619-19-005560 · doc1.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,297 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 18:49 UTC |
Sodhi RajwantPresident, SaaS Business
|
SaleResMed Common Stock | 16,739 | $101.50 | $1,699,008.50 |
DisclosureSEC source: 0001567619-19-005467 · doc1.xml · nonDerivative · entry 1 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,639 Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 18:45 UTC |
Hollingshead JamesPresident, Americas
|
Tax withholdingResMed Common Stock | 832 | $100.45 | $83,574.40 |
DisclosureSEC source: 0001567619-19-004790 · doc1.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,257 F1 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 2/16/2017. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 23:49 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
Exercise / conversionResMed Common Stock Options · Derivative | 3,307 | $0.00 Strike: $43.63 | $0.00 |
DisclosureSEC source: 0001567619-19-004935 · doc1.xml · derivative · entry 4 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,451 Underlying: ResMed Commmon Stock · 3,307 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 23:49 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
SaleResMed Common Stock | 1,006 | $99.95 | $100,549.70 |
DisclosureSEC source: 0001567619-19-004935 · doc1.xml · nonDerivative · entry 3 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Indirect · Douglas Family Trust Disclosed balance after: 154,326 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 23:49 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
SaleResMed Common Stock | 3,307 | $99.95 | $330,534.65 |
DisclosureSEC source: 0001567619-19-004935 · doc1.xml · nonDerivative · entry 2 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,421 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 23:49 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
Exercise / conversionResMed Common Stock | 3,307 | $43.63 | $144,284.41 |
DisclosureSEC source: 0001567619-19-004935 · doc1.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,728 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 22:29 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 4,134 | $0.00 Strike: $43.63 | $0.00 |
DisclosureSEC source: 0001567619-19-003846 · doc1.xml · derivative · entry 7 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,808 Underlying: ResMed Commmon Stock · 4,134 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F4 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 annually. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 22:29 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 2,517 | $0.00 Strike: $43.63 | $0.00 |
DisclosureSEC source: 0001567619-19-003846 · doc1.xml · derivative · entry 6 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Commmon Stock · 2,517 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F4 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 annually. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 22:29 UTC |
Farrell Michael J.Chief Executive Officer
|
SaleResMed Common Stock | 4,134 | $97.22 | $401,911.61 |
DisclosureSEC source: 0001567619-19-003846 · doc1.xml · nonDerivative · entry 4 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,282 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $97.05 to $97.41. The price reported above reflects the weighted average sale price. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 22:29 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock | 4,134 | $43.63 | $180,366.42 |
DisclosureSEC source: 0001567619-19-003846 · doc1.xml · nonDerivative · entry 3 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,416 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 22:29 UTC |
Farrell Michael J.Chief Executive Officer
|
SaleResMed Common Stock | 2,517 | $97.11 | $244,418.32 |
DisclosureSEC source: 0001567619-19-003846 · doc1.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,282 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $96.84 to $97.52. The price reported above reflects the weighted average sale price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.